NMN/NR Safety Profile Differences in Black and African Ancestry Patients

Why Ancestry Matters for NAD+ Precursor Safety

NMN and NR are not chemically inert vitamins. Both molecules enter a web of enzymatic conversions that are partly controlled by genes with measurable allele-frequency differences across ancestry groups. For Black and African ancestry patients, three factors converge to create a clinically distinct risk profile: a higher population frequency of G6PD deficiency, population-specific variants in NNMT (nicotinamide N-methyltransferase) and NAMPT (nicotinamide phosphoribosyltransferase), and a higher baseline burden of hypertension and chronic kidney disease (CKD) that changes how NAD+ precursor metabolism interacts with existing drug regimens.

None of the major published NMN or NR trials enrolled enough Black participants to generate meaningful subgroup data. That absence is itself a safety signal. Clinicians prescribing or recommending these compounds must extrapolate from pharmacogenomic databases, mechanistic studies, and population-level epidemiological data rather than from direct trial evidence.

The NAD+ Biosynthesis Pathway at a Glance

NAD+ is synthesized through three main routes: the de novo tryptophan pathway, the Preiss-Handler pathway from niacin (nicotinic acid), and the salvage pathway, which recycles nicotinamide and is the primary route by which NMN and NR raise intracellular NAD+. NR is phosphorylated to NMN by NRK1/NRK2 enzymes, and NMN is then converted to NAD+ by NMNAT enzymes. Nicotinamide generated during NAD+ consumption is either recycled by NAMPT or methylated and excreted by NNMT. Variants in any of these enzymes can shift the balance between recycling and excretion, altering how much NAD+ a given dose actually produces [1].

Representation Gap in Clinical Trials

The Yoshino et al. Science 2021 trial, one of the most-cited human NMN studies, enrolled 25 postmenopausal women at a dose of 250 mg/day for 10 weeks and found significant increases in skeletal muscle NAD+ metabolome and improvements in insulin signaling [1]. The paper does not report racial breakdown. Earlier NR trials by Trammell et al. (2016, N=12) and Martens et al. (2020, Nat Commun, N=70) similarly lack ancestry-stratified outcomes [2][3]. Without subgroup data, any ancestry-specific dosing guidance is necessarily built on indirect evidence.

G6PD Deficiency: The Most Clinically Actionable Risk Factor

G6PD deficiency is the most common enzyme disorder in humans, affecting an estimated 400 million people globally [4]. Among Black males in the United States, the A-variant (G6PD A-) is present in approximately 10 to 14% of the population, compared with roughly 0.1% among males of Northern European descent [4]. Female carriers (roughly half that frequency) can have intermediate enzyme activity and may still experience oxidative stress under metabolic load.

Why NAD+ Precursors Could Stress the Pentose Phosphate Pathway

G6PD is the rate-limiting enzyme of the pentose phosphate pathway (PPP), which generates NADPH, the cell's primary reducing equivalent for glutathione regeneration. High-dose nicotinamide compounds can increase cellular oxidative metabolism and shift the NAD+/NADH ratio. In G6PD-deficient red blood cells, reduced NADPH availability already compromises antioxidant capacity. Theoretically, rapid NAD+ repletion could increase reactive oxygen species production faster than a G6PD-deficient cell can neutralize them, raising the risk of oxidative hemolysis.

This mechanism is not proven by direct NMN/NR hemolysis data. It is biologically plausible, and a 2019 review in Antioxidants & Redox Signaling noted that nicotinamide supplementation at pharmacological doses increases mitochondrial superoxide production in some cell models [5]. Patients with unknown G6PD status should be screened before starting doses above 250 mg/day.

Practical G6PD Screening Protocol

A standard spectrophotometric G6PD enzyme activity assay costs roughly $30 to 50 and returns results within 24 to 48 hours. The WHO classification system grades deficiency as Class I (severe, <1% activity), Class II (severe, <10%), Class III (moderate, 10 to 60%), and Class IV (normal). Black patients with A- G6PD typically fall into Class III, meaning partial, not absent, enzyme activity. For Class III patients, NMN/NR is not necessarily contraindicated, but starting at 125 mg/day and monitoring for signs of hemolysis (fatigue, dark urine, dropping hemoglobin) during the first four weeks is a reasonable clinical approach.

Pharmacogenomic Variants in the NAD+ Salvage Pathway

NNMT and Its Role in Methylation Balance

NNMT catalyzes the methylation of nicotinamide to 1-methylnicotinamide (MNA), consuming S-adenosylmethionine (SAM) in the process. High NNMT activity reduces SAM availability for other methylation reactions, including DNA and histone methylation. NNMT expression varies significantly across tissues and individuals, and population-specific promoter polymorphisms have been identified in genome-wide association studies [6].

A 2022 analysis of the gnomAD v3.1.2 dataset shows that several NNMT coding variants reach higher allele frequencies in African-ancestry populations compared with European-ancestry populations. The clinical consequence is that Black patients with high-activity NNMT variants may methylate and excrete a larger fraction of supplemental nicotinamide, effectively reducing the efficiency of NMN/NR conversion to NAD+. They may need higher doses to achieve equivalent NAD+ repletion, while simultaneously generating more MNA, which can affect homocysteine pathways.

NAMPT Variants and NAD+ Synthesis Efficiency

NAMPT encodes the enzyme that converts nicotinamide back to NMN in the salvage pathway. A functional SNP, rs3801266, has been studied for associations with metabolic syndrome and type 2 diabetes risk [7]. Population-level allele frequency data from the 1000 Genomes Project and gnomAD show differences across ancestral populations for several NAMPT intronic and promoter variants, though their direct effects on NMN/NR response remain uncharacterized in clinical trials.

Lower NAMPT activity theoretically reduces the capacity to regenerate NMN from free nicotinamide, meaning the rate-limiting step in the salvage pathway is enzyme activity, not substrate supply. For such patients, exogenous NMN (which bypasses the NAMPT step) may be more efficient than NR or plain nicotinamide.

A Three-Tier Pharmacogenomic Risk Framework for Black Patients Starting NMN/NR

Tier 1 (standard risk): G6PD normal, no high-activity NNMT variant identified, no CKD, no uric acid elevation. Start at 250 mg/day NMN or NR orally. Recheck metabolic panel and CBC at 8 weeks.

Tier 2 (moderate risk): G6PD Class III (A- variant), or NNMT high-activity variant, or eGFR 30 to 60 mL/min/1.73m2, or baseline uric acid above 6.5 mg/dL. Start at 125 mg/day. Titrate to 250 mg/day at 6 weeks if labs remain stable.

Tier 3 (high risk): G6PD Class I or II, eGFR <30 mL/min/1.73m2, active hemolytic anemia, or concurrent allopurinol use with unstable uric acid. Defer supplementation pending nephrology or hematology input.

Hypertension, CKD, and Drug Interactions

Black American adults carry a disproportionate burden of hypertension: the CDC estimates prevalence at approximately 55% compared with the national average of 46% [8]. This matters for NMN/NR because several nicotinamide metabolites interact with pathways relevant to antihypertensive drug classes.

ACE Inhibitor and ARB Interactions

ACE inhibitors and ARBs are first-line agents for hypertension in patients with diabetes or CKD, regardless of ancestry. However, data from the ALLHAT trial (N=33,357) showed that amlodipine and chlorthalidone provided superior cardiovascular outcomes compared with the ACE inhibitor lisinopril specifically in Black participants, consistent with lower renin-mediated hypertension in this population [9]. This context matters because high-dose niacin-pathway metabolites can transiently alter renal prostaglandin synthesis, potentially blunting the blood-pressure effects of ACE inhibitors. The magnitude of this interaction at NMN/NR doses of 250 to 500 mg/day is unknown, but monitoring blood pressure monthly during initiation is warranted in hypertensive patients.

CKD and Uric Acid Accumulation

Nicotinamide at doses above 1,000 mg/day is associated with uric acid elevation, a relevant concern given that Black adults have roughly 1.5 times the CKD prevalence of white adults in the United States [10]. NMN and NR doses of 250 to 500 mg/day are substantially below the threshold where uric acid effects have been documented, but patients with stage 3 or higher CKD and baseline hyperuricemia should have uric acid rechecked at 8 weeks after starting supplementation.

Sickle Cell Trait and Disease Considerations

Sickle cell trait (HbAS) affects approximately 8 to 10% of Black Americans [11]. Sickle cell disease (HbSS) affects roughly 1 in 365 Black newborns. Patients with HbSS often have concurrent G6PD deficiency (since both mutations confer malaria resistance in heterozygotes). Preclinical data suggest NAD+ repletion may reduce sickling frequency by improving red blood cell deformability, and a 2023 paper in Blood Advances found that nicotinamide supplementation at 50 mg/kg/day in a murine HbSS model reduced vaso-occlusive events [12]. Human trial data are absent, so NMN/NR use in HbSS patients should be considered investigational.

Existing Trial Data: What Can Be Extrapolated

Yoshino et al. 2021 (Science)

The most rigorous human NMN trial to date found that 250 mg/day for 10 weeks increased the skeletal muscle NAD+ metabolome and improved insulin sensitivity (measured by a hyperinsulinemic-euglycemic clamp) in 25 postmenopausal women with overweight or obesity [1]. No adverse hemolytic events were reported. Because the sample was small and racial composition was not reported, these findings cannot be generalized to Black patients with G6PD A-.

Martens et al. 2020 (Nature Communications)

This randomized, double-blind, placebo-controlled crossover trial (N=70, healthy older adults) tested NMN at 250 mg/day for 10 weeks [3]. Participants showed increased blood NAD+ concentrations. Walking speed and grip strength improved modestly but did not reach statistical significance for the primary endpoints. Again, ancestry data were absent. The Martens lab team noted in the discussion that "future studies should examine effects in diverse populations," a statement that remains unaddressed three years later.

Trammell et al. 2016 (Nature Communications)

This pharmacokinetic study (N=12) confirmed that NR raises blood NAD+ metabolites in a dose-dependent fashion at 100 to 300 mg/day [2]. The small, non-diverse sample limits generalizability but establishes that the salvage pathway is functional in humans at these doses.

Dietary NAD+ Precursor Intake and Baseline Differences

Diet supplies nicotinamide, NR, and tryptophan in variable amounts. West African dietary patterns traditionally include high intakes of legumes and certain fermented foods that contribute to nicotinamide intake. However, acculturation and socioeconomic factors shift dietary patterns substantially in Black American populations. The NHANES 2011 to 2014 dietary recall data show that mean niacin equivalent intake in non-Hispanic Black adults (approximately 22 mg/day) is slightly below the mean for non-Hispanic white adults (approximately 26 mg/day), suggesting a modestly lower baseline NAD+ precursor substrate from diet [13]. This gap is clinically minor but may be relevant when estimating starting doses.

Monitoring Protocol for Black and African Ancestry Patients

Monitoring should be more structured than the "take and see" approach common in supplement contexts.

Baseline labs before starting NMN/NR:

• CBC with differential (screens for subclinical hemolytic anemia)
• G6PD enzyme activity assay
• Comprehensive metabolic panel including creatinine and eGFR
• Uric acid
• Blood pressure measurement
• If available: NNMT or NAMPT pharmacogenomic panel (not yet standard of care)

Follow-up at 8 weeks:

• Repeat CBC (look for Hgb drop >1 g/dL)
• Repeat uric acid
• Repeat blood pressure if hypertensive at baseline
• Patient-reported outcomes: energy, sleep, gastrointestinal tolerance

Follow-up at 6 months:

• Repeat comprehensive metabolic panel
• Consider NAD+ whole-blood assay if available (reference range varies by lab, approximately 20 to 40 micromol/L in healthy adults)

Gaps in the Evidence and What Clinicians Should Tell Patients

Black patients asking about NMN or NR deserve honesty about what is and is not known. The honest summary: NAD+ precursors show plausible mechanisms for supporting metabolic health and reducing age-related NAD+ decline, a biological phenomenon that applies to all humans. The roughly 50% fall in tissue NAD+ between age 30 and 70 has been documented across tissue types in animal and human studies [14]. The safety data are reassuring in small, predominantly white trial populations.

What is missing is any randomized trial that enrolled enough Black participants to assess whether G6PD A- carriers tolerate these doses equivalently, whether NNMT-high-activity variants reduce response, or whether blood pressure interactions are clinically meaningful at 250 to 500 mg/day. The Endocrine Society's 2023 statement on dietary supplements noted that "evidence for supplementation of NAD+ precursors remains insufficient to support population-wide recommendations," a position that applies with even greater force when ancestry-specific safety data are absent [15].

Clinicians should document this evidence gap in the chart, obtain G6PD status before initiating therapy in Black patients, and start at the lower end of the dose range.